Polycystic Ovary Syndrome (PCOS): Symptoms, Diagnosis, and Treatment

Polycystic ovary syndrome is one of the most common endocrine disorders affecting people with ovaries, estimated to affect between 6% and 12% of US women of reproductive age according to the Centers for Disease Control and Prevention (CDC). The condition disrupts hormonal signaling, menstrual regularity, and metabolic function simultaneously, making it both a reproductive and a systemic health concern. This page covers the defining features, underlying mechanisms, diagnostic criteria, treatment categories, contested areas, and persistent misconceptions surrounding PCOS.

Definition and Scope

PCOS is a heterogeneous endocrine disorder defined by the coexistence of hormonal imbalance, ovulatory dysfunction, and characteristic ovarian morphology. The World Health Organization (WHO) identifies PCOS as the leading cause of anovulatory infertility globally. In the United States, the condition disproportionately contributes to diagnoses of type 2 diabetes, metabolic syndrome, and endometrial hyperplasia across affected populations.

The syndrome does not resolve spontaneously at reproductive age boundaries. Metabolic sequelae — including insulin resistance and dyslipidemia — persist through perimenopause and beyond, a dimension addressed under perimenopause management frameworks. For a broader orientation to the regulatory and clinical landscape governing women's endocrine health, the regulatory context for women's health provides applicable statutory and agency framing.

The CDC estimates that up to 70% of affected individuals remain undiagnosed, a gap attributable to symptom variability and the absence of a single confirmatory biomarker (CDC, PCOS fact sheet).

Core Mechanics or Structure

PCOS operates through three interlocking axes: hypothalamic-pituitary signaling abnormality, androgen excess, and insulin dysregulation.

Hypothalamic-Pituitary Axis Disruption
In PCOS, the pulsatile release of gonadotropin-releasing hormone (GnRH) is accelerated. This drives disproportionately elevated luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). The resulting LH:FSH ratio — frequently exceeding 2:1 or 3:1 in classic presentations — stimulates theca cells in the ovary to produce excess androgens while suppressing the FSH signal needed for follicle maturation and ovulation.

Androgen Excess
Elevated androgens, primarily testosterone and androstenedione, produce the clinical signs most visible to patients: hirsutism (excess terminal hair in androgen-sensitive areas), acne, and androgenic alopecia. The Endocrine Society's Clinical Practice Guideline on PCOS (2023) designates biochemical hyperandrogenism as a central diagnostic criterion.

Ovarian Morphology
Follicles arrested at 2–9 mm in diameter accumulate along the ovarian cortex, producing the "polycystic" appearance on ultrasound. The Rotterdam Criteria (established in 2003 by a joint European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine [ESHRE/ASRM] consensus) define polycystic ovarian morphology as 12 or more follicles per ovary measuring 2–9 mm, or an ovarian volume exceeding 10 mL.

Insulin Resistance
Approximately 50–70% of individuals with PCOS exhibit insulin resistance independent of body weight, according to research cited in the Endocrine Society's guidelines. Hyperinsulinemia amplifies LH-driven androgen production in theca cells and suppresses sex hormone-binding globulin (SHBG), increasing free androgen bioavailability.

Causal Relationships or Drivers

No single causative gene for PCOS has been identified. The condition is understood as polygenic with strong environmental modifiers.

Genetic Contributions
First-degree relatives of individuals with PCOS carry a substantially elevated risk. Twin studies suggest heritability estimates between 70% and 79%, as reported in analyses published through the National Institutes of Health (NIH) National Library of Medicine. Candidate gene research implicates loci involved in insulin signaling, steroidogenesis, and gonadotropin action.

Prenatal Androgen Exposure
Animal model research, referenced in NIH-funded studies, demonstrates that prenatal androgen exposure programs hypothalamic GnRH pulse generators toward the hyperactive pattern characteristic of PCOS, suggesting developmental origins extending before birth.

Adipose Tissue and Weight
Excess adipose tissue amplifies insulin resistance and peripheral androgen conversion via aromatase activity, worsening the hormonal milieu. However, PCOS is not caused by excess weight — lean individuals with body mass indices within normal ranges develop the full clinical syndrome. The Office on Women's Health (OWH) explicitly notes that PCOS occurs across all body sizes.

Classification Boundaries

The four Rotterdam phenotypes define the diagnostic space for PCOS and carry distinct metabolic risk profiles.

Phenotype Hyperandrogenism Oligo-anovulation Polycystic Ovarian Morphology Metabolic Risk
A (Classic) ✓ ✓ ✓ Highest
B (Classic) ✓ ✓ ✗ High
C (Ovulatory) ✓ ✗ ✓ Moderate
D (Non-androgenic) ✗ ✓ ✓ Lower

Phenotype A carries the highest risk for metabolic syndrome, insulin resistance, and cardiovascular markers. Phenotype D is the most contested, as its exclusion of hyperandrogenism challenges the androgen-centric mechanistic framework. The Androgen Excess and PCOS Society has formally argued that hyperandrogenism should remain a required criterion, diverging from the Rotterdam framework.

Differential diagnosis requires ruling out thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia (CAH), and androgen-secreting neoplasms — all of which can mimic PCOS features. Thyroid disorders in women and adrenal health and hormonal balance cover those adjacent conditions in detail.

Tradeoffs and Tensions

Diagnostic Criterion Disputes
The Rotterdam Criteria are broader than the earlier 1990 NIH criteria, which required both hyperandrogenism and oligo-anovulation. Adopting Rotterdam increased PCOS prevalence estimates substantially and incorporated phenotypes (particularly Phenotype D) that some endocrinologists argue represent distinct conditions rather than PCOS variants.

Pharmacological Management Tensions
Combined oral contraceptives regulate menstrual cycling and reduce androgen levels but do not address underlying insulin resistance. Metformin targets insulin resistance but produces more modest menstrual and androgenic improvements. The Endocrine Society's 2023 guidelines describe this as a priority-dependent choice rather than a clear hierarchy, since the most appropriate intervention depends on the patient's primary presenting concern — fertility, androgen symptoms, or metabolic risk.

Weight-Centric Framing
Clinical guidance has historically emphasized weight reduction as a primary intervention, which the OWH and patient advocacy organizations such as PCOS Awareness Association have criticized for creating diagnostic and care barriers for lean individuals and contributing to delayed diagnosis. The 2023 Endocrine Society guideline revision incorporated patient input explicitly to address this tension.

Long-Term Cancer Risk
Chronic anovulation produces unopposed estrogen exposure to the endometrial lining, elevating endometrial hyperplasia and endometrial cancer risk. The magnitude of this risk elevation is documented in uterine and endometrial cancer clinical literature, though quantification varies across study populations.

Common Misconceptions

Misconception: PCOS always causes cysts on the ovaries.
Correction: The "cysts" referenced in the name are arrested follicles, not true cysts. They are fluid-filled follicular structures that failed to ovulate. A diagnosis of PCOS does not require polycystic ovarian morphology under either the NIH 1990 or Rotterdam frameworks — Phenotype B lacks this feature entirely. True ovarian cysts are a distinct category; see ovarian cysts for that distinction.

Misconception: PCOS means infertility is certain.
Correction: PCOS causes anovulatory infertility, meaning ovulation is irregular or absent — not that conception is impossible. Ovulation induction with agents such as letrozole or clomiphene citrate restores ovulation in a substantial proportion of cases. The NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) documents that PCOS is treatable as a cause of infertility.

Misconception: PCOS resolves after menopause.
Correction: Reproductive symptoms (irregular cycles, anovulation) resolve with the cessation of ovarian cycling, but metabolic features — insulin resistance, dyslipidemia, elevated cardiovascular risk markers — persist and may intensify without active management.

Misconception: Only overweight individuals develop PCOS.
Correction: As noted by the OWH, lean PCOS is a recognized and documented presentation. Androgen excess and anovulation occur across body weight categories.

Checklist or Steps (Non-Advisory)

The following sequence reflects the standard diagnostic and management evaluation pathway described in Endocrine Society Clinical Practice Guidelines and NICHD guidance. This is a structural description of the process — not clinical advice.

Diagnostic Evaluation Sequence

  1. Clinical history — Document menstrual cycle pattern (frequency, regularity), androgen symptom onset, fertility goals, and family history of PCOS or type 2 diabetes.
  2. Physical examination — Assessment for hirsutism (scored via the Ferriman-Gallwey scale, with a score ≥8 considered indicative in most populations), acne distribution, and signs of insulin resistance (e.g., acanthosis nigricans).
  3. Serum androgen measurement — Total and free testosterone; DHEAS if adrenal source is suspected; SHBG to calculate free androgen index.
  4. Exclusion of mimics — TSH to exclude thyroid dysfunction; prolactin to exclude hyperprolactinemia; 17-hydroxyprogesterone (early morning, follicular phase) to exclude non-classic CAH.
  5. LH:FSH ratio assessment — Elevated LH relative to FSH supports but does not independently confirm diagnosis.
  6. Pelvic ultrasound — Transvaginal preferred for follicle counting; transabdominal used when transvaginal is not appropriate. Rotterdam threshold: ≥12 follicles (2–9 mm) per ovary or ovarian volume >10 mL.
  7. Metabolic screening — Fasting glucose, fasting insulin, lipid panel, and hemoglobin A1c to characterize metabolic risk.
  8. Apply diagnostic criteria — Confirm at least 2 of 3 Rotterdam criteria (hyperandrogenism, oligo-anovulation, polycystic ovarian morphology) after exclusion of other causes.
  9. Phenotype classification — Assign Rotterdam phenotype (A–D) to guide risk stratification and treatment prioritization.
  10. Goal-directed management planning — Separate treatment tracks for cycle regulation, androgen symptom management, insulin resistance, and fertility are coordinated based on phenotype and patient priorities per Endocrine Society framework.

Reference Table or Matrix

The table below compares primary pharmacological interventions used in PCOS management across four clinical domains, drawing on Endocrine Society 2023 guidelines and NICHD clinical summaries.

Intervention Cycle Regulation Androgen Reduction Insulin Resistance Fertility Promotion
Combined oral contraceptive (COC) ✓ Primary ✓ Strong ✗ ✗ Contraindicated
Metformin ✓ Moderate ✓ Indirect ✓ Primary ✓ Adjunct
Letrozole (aromatase inhibitor) ✗ ✗ ✗ ✓ First-line
Clomiphene citrate ✗ ✗ ✗ ✓ Second-line
Spironolactone ✗ ✓ Strong ✗ ✗ Contraindicated in pregnancy
Inositol (myo-inositol) ✓ Emerging ✓ Mild ✓ Emerging ✓ Emerging
Lifestyle modification ✓ Moderate ✓ Indirect ✓ Strong ✓ Adjunct

Inositol evidence is classified as emerging in the 2023 Endocrine Society revision; it is not yet a first-line recommendation but is acknowledged as having a favorable safety profile. Spironolactone carries a teratogenicity risk (FDA Pregnancy Category C/D classifications), making concurrent contraception required when prescribed for androgen management.

The broader context of women's reproductive health conditions — including the relationship between PCOS and fertility and conception outcomes — is covered across the Women's Health Authority home resource.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)